Reduced Hospital Mortality With Surgical Ligation of Patent Ductus Arteriosus in Premature, Extremely Low Birth Weight Infants: A Propensity Score-matched Outcome Study

Objectives:To evaluate outcomes after surgical ligation (SL) of patent ductus arteriosus (PDA) in premature, extremely low birth weight (ELBW) infants. Background:Optimal management of PDA in this specialized population remains undefined. Currently, surgical therapy is largely reserved for infants failing medical management. To date, a large-scale, risk-matched population-based study has not been performed to evaluate differences in mortality and resource utilization. Methods:Data on identified premature (<37 weeks) and ELBW (<1000 g) infants with PDA (International Classification of Diseases, 9th revision, Clinical Modification, 747.0) and respiratory distress (769) were obtained from Kids’ Inpatient Database (2003–2009). Results:Overall, 12,470 cases were identified, with 3008 undergoing SL. Propensity score-matched analysis of 1620 SL versus 1584 non-SL found reduced mortality (15% vs 26%) and more routine disposition (48% vs 41%) for SL (P < 0.001). SL had longer length of stay and higher total cost (P < 0.001). On multivariate analysis, SL mortality predictors were necrotizing enterocolitis (NEC; surgical odds ratio, 5.95; medical odds ratio, 4.42) and sepsis (3.43) (P < 0.006). Length of stay increased with bronchopulmonary dysplasia (BPD; 1.77), whereas total cost increased with surgical NEC (1.82) and sepsis (1.26) (P < 0.04). Non-SL mortality predictors were NEC (surgical, 76.3; medical, 6.17), sepsis (2.66), and intraventricular hemorrhage (1.97) (P < 0.005). Length of stay increased with BPD (2.92) and NEC (surgical, 2.04; medical, 1.28) (P < 0.03). Total cost increased with surgical NEC (2.06), medical NEC (1.57), sepsis (1.43), and BPD (1.30) (P < 0.001). Conclusions:Propensity score-matched analysis demonstrates reduced mortality in premature/ELBW infants with SL for PDA. NEC and sepsis are predictors of mortality and resource utilization.

[1]  Elaine L. Shelton,et al.  Patent Ductus Arteriosus of the Preterm Infant , 2020, Pediatrics.

[2]  J. Tashiro,et al.  A nationwide analysis of clinical outcomes among newborns with esophageal atresia and tracheoesophageal fistulas in the United States. , 2014, The Journal of surgical research.

[3]  J. Tashiro,et al.  Patent ductus arteriosus ligation in premature infants in the United States. , 2014, The Journal of surgical research.

[4]  P. McNamara,et al.  Patent Ductus Arteriosus Ligation and Adverse Outcomes: Causality or Bias? , 2014, Journal of clinical neonatology.

[5]  P. McNamara,et al.  PDA Ligation and Health Outcomes: A Meta-analysis , 2014, Pediatrics.

[6]  So-Young Kim,et al.  Outcomes of Primary Ligation of Patent Ductus Arteriosus Compared With Secondary Ligation After Pharmacologic Failure in Very-Low-Birth-Weight Infants , 2013, Pediatric Cardiology.

[7]  D. LaPar,et al.  The effect of race and gender on pediatric surgical outcomes within the United States. , 2013, Journal of pediatric surgery.

[8]  M. Rockoff,et al.  "A thrill of extreme magnety": Robert E. Gross and the beginnings of cardiac surgery. , 2013, Journal of pediatric surgery.

[9]  James S. Davis,et al.  ECMO hospital volume and survival in congenital diaphragmatic hernia repair. , 2012, The Journal of surgical research.

[10]  A. Ohlsson,et al.  Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. , 2011, The Cochrane database of systematic reviews.

[11]  Gary King,et al.  MatchIt: Nonparametric Preprocessing for Parametric Causal Inference , 2011 .

[12]  A. Deorari,et al.  Patent ductus arteriosus in preterm infants , 2011, Indian pediatrics.

[13]  S. Noori,et al.  Patent ductus arteriosus in the preterm infant: to treat or not to treat? , 2010, Journal of Perinatology.

[14]  L. Koniaris,et al.  Survival disparities in newborns with congenital diaphragmatic hernia: a national perspective. , 2010, Journal of pediatric surgery.

[15]  G. Cassady,et al.  The role of patent ductus arteriosus ligation in bronchopulmonary dysplasia: reexamining a randomized controlled trial. , 2009, The Journal of pediatrics.

[16]  J. Hagadorn,et al.  Patent Ductus Arteriosus Therapy: Impact on Neonatal and 18-Month Outcome , 2009, Pediatrics.

[17]  R. Polin,et al.  The ductus arteriosus rarely requires treatment in infants > 1000 grams. , 2008, American journal of perinatology.

[18]  K. Alfaleh,et al.  Prophylactic surgical ligation of patent ductus arteriosus for prevention of mortality and morbidity in extremely low birth weight infants. , 2008, The Cochrane database of systematic reviews.

[19]  M. Laughon,et al.  Patent ductus arteriosus: lack of evidence for common treatments , 2007, Archives of Disease in Childhood Fetal and Neonatal Edition.

[20]  P. Davis,et al.  Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants. , 2007, The Cochrane database of systematic reviews.

[21]  L. Doyle,et al.  Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. , 2007, The Journal of pediatrics.

[22]  C. Ramaciotti,et al.  Prevalence of Spontaneous Closure of the Ductus Arteriosus in Neonates at a Birth Weight of 1000 Grams or Less , 2006, Pediatrics.

[23]  C. Rosenfeld,et al.  Hospital Survival of Very-Low-Birth-Weight Neonates from 1977 to 2000 , 2004, Journal of Perinatology.

[24]  Y. Weng,et al.  Patent ductus arteriosus in very low birthweight infants: complications of pharmacological and surgical treatment , 2001, Journal of perinatal medicine.

[25]  T. Trus,et al.  Optimal management of patent ductus arteriosus in the neonate weighing less than 800 g. , 1993, Journal of pediatric surgery.

[26]  G. Cassady,et al.  A randomized, controlled trial of very early prophylactic ligation of the ductus arteriosus in babies who weighed 1000 g or less at birth. , 1989, The New England journal of medicine.

[27]  M. Schwartz,et al.  Management of patent ductus arteriosus: a comparison of operative v pharmacologic treatment. , 1987, Journal of pediatric surgery.

[28]  D. LaPar,et al.  Primary payer status is significantly associated with postoperative mortality, morbidity, and hospital resource utilization in pediatric surgical patients within the United States. , 2013, Journal of pediatric surgery.

[29]  P. Mandhan,et al.  Surgical closure of patent ductus arteriosus in preterm low birth weight infants. , 2009, Congenital heart disease.

[30]  A. Ohlsson,et al.  Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants. , 2008, The Cochrane database of systematic reviews.

[31]  C. Steiner,et al.  Comorbidity measures for use with administrative data. , 1998, Medical care.